| |
|
|
|
Nymox Pharmaceutical Corporation  
|
|
2.6 -0.11 (-0.04%) |
02-19 16:00 |
|
Open: |
2.74 |
Pre close: |
2.71 |
Target:
|
3.21 
|
|
High: |
2.75 |
Low: |
2.53 |
Resistance:
|
2.75
3.21
|
|
Volume: |
58,514 |
Market Cap: |
166M |
Support:
|
2.17
1.81
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
2.52
|
MACD |
MACD(12,26):
|
0.17 |
|
MA(20): |
2.29 |
Signal(12,26,9): |
0.15 |
|
MA(100): |
1.95 |
Stochastic Oscillator |
%K(14,3):
|
81.46  |
|
MA(250): |
2.86 |
%D(3): |
80.20 |
|
Average Volume(K) |
3-Month: |
8917
|
52-Week |
High:
|
4.60 |
|
10-Days: |
7314 |
Low: |
1.25 |
|
RSI |
RSI(14):
|
69.63 |
Change(%): |
-18.5 |
|
Financials, Statistics and Valuation |
|
EPS |
0.000 |
Return on Equity (ttm) |
-568.8 |
Shares Out. (M) |
63.72 |
|
EPS Est. Current Year |
-0.200 |
Return on Assets (ttm) |
-341.4 |
Shares Float (M) |
36.90 |
|
EPS Est. Next Year |
-0.570 |
PEG Ratio |
0.00 |
% Held by Insiders |
0.00 |
|
EPS Est. Next Quarter |
0.000 |
Qtrly Rev. Growth |
29.0 |
% Held by Institutions |
10.40 |
|
Forward EPS |
1.#IO |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
0 |
|
Book Value (p.s.) |
37.620 |
EBITDA (p.s.) |
0.000 |
P/E |
0.00 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
0.07 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-7.38 |
P/S |
16567198720.00 |
|
Operating Margin |
-2908.31 |
Levered Free Cash Flow
(M) |
-3.21 |
P/CF |
-22.45 |
|
|
|
|
|
|
